Nurix Therapeutics (NASDAQ:NRIX – Get Free Report)‘s stock had its “overweight” rating restated by Stephens in a report issued on Tuesday,Benzinga reports. They currently have a $31.00 target price on ...

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients ...

SAN FRANCISCO - Nurix Therapeutics, Inc. (NASDAQ:NRIX), a biopharmaceutical company specializing in targeted protein modulation drugs, announced today the appointment of John Northcott as its new ...

Mr. Northcott brings over 20 years of biopharmaceutical experience building commercial organizations and successfully commercializing novel products, including BTK inhibitor ibrutinibSAN FRANCISCO, ...

Dr. Beaurang has over 25 years of experience in biotechnology focusing on corporate strategy, business development, oncology, immunology and neurology. Dr. Beaurang was most recently CEO and member of ...

In a report released today, Jeet Mukherjee from BTIG maintained a Buy rating on Nurix Therapeutics (NRIX – Research Report), with a price ...

Since it has a market capitalisation of US$1.4b, Nurix Therapeutics' US$107m in cash burn equates to about 7.9% of its market value. Given that is a rather small percentage, it would probably be ...

Check the time stamp on this data. Updated AI-Generated Signals for Nurix Therapeutics Inc. (NRIX) available here: NRIX. Type ...

Barclays analyst Peter Lawson maintained a Buy rating on Nurix Therapeutics (NRIX – Research Report) today and set a price target of $31.00.

Nurix Therapeutics (NRIX) leads in targeted protein modulation with its DELigase platform, developing BTK degraders like NX-5948. The company’s DELigase platform allows for targeted protein ...